Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Secondary enucleated retinoblastoma with MYCN amplification.

Ophthalmic genetics

Moulin AP, Stathopoulos C, Marcelli F, Schoumans Pouw J, Beck-Popovic M, Munier FL.
PMID: 33870828
Ophthalmic Genet. 2021 Jun;42(3):354-359. doi: 10.1080/13816810.2021.1897847. Epub 2021 Apr 19.

No abstract available.

Cite
Moulin AP, Stathopoulos C, Marcelli F, et al. Secondary enucleated retinoblastoma with MYCN amplification. Ophthalmic Genet. 2021;42(3):354-359doi: 10.1080/13816810.2021.1897847.
Moulin, A. P., Stathopoulos, C., Marcelli, F., Schoumans Pouw, J., Beck-Popovic, M., & Munier, F. L. (2021). Secondary enucleated retinoblastoma with MYCN amplification. Ophthalmic genetics, 42(3), 354-359. https://doi.org/10.1080/13816810.2021.1897847
Moulin, Alexandre P, et al. "Secondary enucleated retinoblastoma with MYCN amplification." Ophthalmic genetics vol. 42,3 (2021): 354-359. doi: https://doi.org/10.1080/13816810.2021.1897847
Moulin AP, Stathopoulos C, Marcelli F, Schoumans Pouw J, Beck-Popovic M, Munier FL. Secondary enucleated retinoblastoma with MYCN amplification. Ophthalmic Genet. 2021 Jun;42(3):354-359. doi: 10.1080/13816810.2021.1897847. Epub 2021 Apr 19. PMID: 33870828.
Copy Download .nbib Format: NLM
Intracameral Chemotherapy (Melphalan) for Aqueous Seeding in Retinoblastoma: Bicameral Injection Technique and Related Toxicity in a Pilot Case Study.

Ocular oncology and pathology

Munier FL, Gaillard MC, Decembrini S, Bongiovanni M, Beck-Popovic M.
PMID: 28868287
Ocul Oncol Pathol. 2017 Jul;3(2):149-155. doi: 10.1159/000453617. Epub 2016 Dec 29.

BACKGROUND: The anterior chamber has been shown by pharmacokinetic studies to represent a sanctuary never achieving a tumoricidal dose with the present administration routes, such as systemic, intra-arterial, or intravitreal injections.METHOD: A novel intracameral chemotherapy technique is described to...

Cite
Munier FL, Gaillard MC, Decembrini S, et al. Intracameral Chemotherapy (Melphalan) for Aqueous Seeding in Retinoblastoma: Bicameral Injection Technique and Related Toxicity in a Pilot Case Study. Ocul Oncol Pathol. 2016;3(2):149-155doi: 10.1159/000453617.
Munier, F. L., Gaillard, M. C., Decembrini, S., Bongiovanni, M., & Beck-Popovic, M. (2017). Intracameral Chemotherapy (Melphalan) for Aqueous Seeding in Retinoblastoma: Bicameral Injection Technique and Related Toxicity in a Pilot Case Study. Ocular oncology and pathology, 3(2), 149-155. https://doi.org/10.1159/000453617
Munier, Francis L, et al. "Intracameral Chemotherapy (Melphalan) for Aqueous Seeding in Retinoblastoma: Bicameral Injection Technique and Related Toxicity in a Pilot Case Study." Ocular oncology and pathology vol. 3,2 (2017): 149-155. doi: https://doi.org/10.1159/000453617
Munier FL, Gaillard MC, Decembrini S, Bongiovanni M, Beck-Popovic M. Intracameral Chemotherapy (Melphalan) for Aqueous Seeding in Retinoblastoma: Bicameral Injection Technique and Related Toxicity in a Pilot Case Study. Ocul Oncol Pathol. 2017 Jul;3(2):149-155. doi: 10.1159/000453617. Epub 2016 Dec 29. PMID: 28868287; PMCID: PMC5566720.
Copy Download .nbib Format: NLM
Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society

Munier FL, Gaillard MC, Balmer A, Beck-Popovic M.
PMID: 24227979
Saudi J Ophthalmol. 2013 Jul;27(3):147-50. doi: 10.1016/j.sjopt.2013.06.003.

For decades intravitreal chemotherapy (IViC) remained virtually banished from the therapeutic armamentarium against retinoblastoma, except as a heroic attempt of salvage before enucleation in only eyes with refractory vitreous seeding. Very recently, we have initiated a reappraisal of this...

Cite
Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives. Saudi J Ophthalmol. 2013;27(3):147-50doi: 10.1016/j.sjopt.2013.06.003.
Munier, F. L., Gaillard, M. C., Balmer, A., & Beck-Popovic, M. (2013). Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives. Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society, 27(3), 147-50. https://doi.org/10.1016/j.sjopt.2013.06.003
Munier, Francis L, et al. "Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives." Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society vol. 27,3 (2013): 147-50. doi: https://doi.org/10.1016/j.sjopt.2013.06.003
Munier FL, Gaillard MC, Balmer A, Beck-Popovic M. Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives. Saudi J Ophthalmol. 2013 Jul;27(3):147-50. doi: 10.1016/j.sjopt.2013.06.003. PMID: 24227979; PMCID: PMC3770220.
Copy Download .nbib Format: NLM
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).

Cancers

Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chi Fung Chan G, Ruud E, Schroeder H, Beck-Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN.
PMID: 32013055
Cancers (Basel). 2020 Jan 28;12(2). doi: 10.3390/cancers12020309.

To explore the effects of immunotherapy in the International Society of Paediatric Oncology Europe Neuroblastoma Group SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1 trial), two cohorts were studied: one prior to and one after the introduction of dinutuximab beta. All...

Cite
Ladenstein R, Pötschger U, Valteau-Couanet D, et al. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers (Basel). 2020;12(2)doi: 10.3390/cancers12020309.
Ladenstein, R., Pötschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Ash, S., Laureys, G., Brock, P., Michon, J. M., Owens, C., Trahair, T., Chi Fung Chan, G., Ruud, E., Schroeder, H., Beck-Popovic, M., Schreier, G., Loibner, H., Ambros, P., Holmes, K., Castellani, M. R., Gaze, M. N., Garaventa, A., Pearson, A. D. J., & Lode, H. N. (2020). Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers, 12(2), . https://doi.org/10.3390/cancers12020309
Ladenstein, Ruth, et al. "Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)." Cancers vol. 12,2 (2020). doi: https://doi.org/10.3390/cancers12020309
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chi Fung Chan G, Ruud E, Schroeder H, Beck-Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers (Basel). 2020 Jan 28;12(2). doi: 10.3390/cancers12020309. PMID: 32013055; PMCID: PMC7072500.
Copy Download .nbib Format: NLM
PASTEC - a prospective, single-center, randomized, cross-over trial of pure physical versus physical plus attentional training in children with cancer.

Pediatric hematology and oncology

Fontana A, Matthey S, Mayor C, Dufour C, Destaillats A, Ballabeni P, Maeder S, Newman CJ, Beck Popovic M, Renella R, Diezi M.
PMID: 34752205
Pediatr Hematol Oncol. 2021 Nov 09;1-14. doi: 10.1080/08880018.2021.1994677. Epub 2021 Nov 09.

Despite recent improvements in survival rates in children with cancer, long-term toxicities remain a major concern. Physical activity could reduce the impact of long-term sequelae, notably in neuropsychological and physical areas. We report of a randomized trial of pure...

Cite
Fontana A, Matthey S, Mayor C, et al. PASTEC - a prospective, single-center, randomized, cross-over trial of pure physical versus physical plus attentional training in children with cancer. Pediatr Hematol Oncol. 2021;1-14doi: 10.1080/08880018.2021.1994677.
Fontana, A., Matthey, S., Mayor, C., Dufour, C., Destaillats, A., Ballabeni, P., Maeder, S., Newman, C. J., Beck Popovic, M., Renella, R., & Diezi, M. (2021). PASTEC - a prospective, single-center, randomized, cross-over trial of pure physical versus physical plus attentional training in children with cancer. Pediatric hematology and oncology, 1-14. https://doi.org/10.1080/08880018.2021.1994677
Fontana, Andrea, et al. "PASTEC - a prospective, single-center, randomized, cross-over trial of pure physical versus physical plus attentional training in children with cancer." Pediatric hematology and oncology vol. (2021): 1-14. doi: https://doi.org/10.1080/08880018.2021.1994677
Fontana A, Matthey S, Mayor C, Dufour C, Destaillats A, Ballabeni P, Maeder S, Newman CJ, Beck Popovic M, Renella R, Diezi M. PASTEC - a prospective, single-center, randomized, cross-over trial of pure physical versus physical plus attentional training in children with cancer. Pediatr Hematol Oncol. 2021 Nov 09;1-14. doi: 10.1080/08880018.2021.1994677. Epub 2021 Nov 09. PMID: 34752205.
Copy Download .nbib Format: NLM
Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams.

Frontiers in oncology

Vuattoux D, Colomer-Lahiguera S, Fernandez PA, Jequier Gygax M, Choucair ML, Beck-Popovic M, Diezi M, Manificat S, Latifyan S, Ramelet AS, Eicher M, Chabane N, Renella R.
PMID: 33552969
Front Oncol. 2021 Jan 19;10:595734. doi: 10.3389/fonc.2020.595734. eCollection 2020.

Delivering optimal cancer care to children, adolescents and adults with ASD has recently become a healthcare priority and represents a major challenge for all providers involved. In this review, and after consideration of the available evidence, we concisely deliver...

Cite
Vuattoux D, Colomer-Lahiguera S, Fernandez PA, et al. Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams. Front Oncol. 2021;10:595734doi: 10.3389/fonc.2020.595734.
Vuattoux, D., Colomer-Lahiguera, S., Fernandez, P. A., Jequier Gygax, M., Choucair, M. L., Beck-Popovic, M., Diezi, M., Manificat, S., Latifyan, S., Ramelet, A. S., Eicher, M., Chabane, N., & Renella, R. (2020). Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams. Frontiers in oncology, 10595734. https://doi.org/10.3389/fonc.2020.595734
Vuattoux, Delphine, et al. "Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams." Frontiers in oncology vol. 10 (2020): 595734. doi: https://doi.org/10.3389/fonc.2020.595734
Vuattoux D, Colomer-Lahiguera S, Fernandez PA, Jequier Gygax M, Choucair ML, Beck-Popovic M, Diezi M, Manificat S, Latifyan S, Ramelet AS, Eicher M, Chabane N, Renella R. Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams. Front Oncol. 2021 Jan 19;10:595734. doi: 10.3389/fonc.2020.595734. eCollection 2020. PMID: 33552969; PMCID: PMC7856416.
Copy Download .nbib Format: NLM
Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition): Protocol for a Multicenter Observational Study.

JMIR research protocols

Belle FN, Beck Popovic M, Ansari M, Otth M, Kuehni CE, Bochud M.
PMID: 31738177
JMIR Res Protoc. 2019 Nov 18;8(11):e14427. doi: 10.2196/14427.

BACKGROUND: Childhood cancer survivors are at high risk of developing adverse late health effects. Poor nutritional intake may contribute to this risk, but information about dietary intake is limited.OBJECTIVE: This study will assess childhood cancer survivors' dietary intake and...

Cite
Belle FN, Beck Popovic M, Ansari M, et al. Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition): Protocol for a Multicenter Observational Study. JMIR Res Protoc. 2019;8(11):e14427doi: 10.2196/14427.
Belle, F. N., Beck Popovic, M., Ansari, M., Otth, M., Kuehni, C. E., & Bochud, M. (2019). Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition): Protocol for a Multicenter Observational Study. JMIR research protocols, 8(11), e14427. https://doi.org/10.2196/14427
Belle, Fabiën Naomi, et al. "Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition): Protocol for a Multicenter Observational Study." JMIR research protocols vol. 8,11 (2019): e14427. doi: https://doi.org/10.2196/14427
Belle FN, Beck Popovic M, Ansari M, Otth M, Kuehni CE, Bochud M. Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition): Protocol for a Multicenter Observational Study. JMIR Res Protoc. 2019 Nov 18;8(11):e14427. doi: 10.2196/14427. PMID: 31738177; PMCID: PMC6887820.
Copy Download .nbib Format: NLM
Corrigendum to "Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "Alive, with good vision and no comorbidity"" [Prog. Retina Eye Res. 73 (2019) 100764].

Progress in retinal and eye research

Munier FL, Beck-Popovic M, Chantada GL, Cobrinik D, Kivelä TT, Lohmann D, Maeder P, Moll AC, Carcaboso AM, Moulin A, Schaiquevich P, Bergin C, Dyson PJ, Houghton S, Puccinelli F, Vial Y, Gaillard MC, Stathopoulos C.
PMID: 32278633
Prog Retin Eye Res. 2020 Apr 08;100857. doi: 10.1016/j.preteyeres.2020.100857. Epub 2020 Apr 08.

No abstract available.

Cite
Munier FL, Beck-Popovic M, Chantada GL, et al. Corrigendum to "Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "Alive, with good vision and no comorbidity"" [Prog. Retina Eye Res. 73 (2019) 100764]. Prog Retin Eye Res. 2020;100857doi: 10.1016/j.preteyeres.2020.100857.
Munier, F. L., Beck-Popovic, M., Chantada, G. L., Cobrinik, D., Kivelä, T. T., Lohmann, D., Maeder, P., Moll, A. C., Carcaboso, A. M., Moulin, A., Schaiquevich, P., Bergin, C., Dyson, P. J., Houghton, S., Puccinelli, F., Vial, Y., Gaillard, M. C., & Stathopoulos, C. (2020). Corrigendum to "Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "Alive, with good vision and no comorbidity"" [Prog. Retina Eye Res. 73 (2019) 100764]. Progress in retinal and eye research, 100857. https://doi.org/10.1016/j.preteyeres.2020.100857
Munier, Francis L, et al. "Corrigendum to "Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "Alive, with good vision and no comorbidity"" [Prog. Retina Eye Res. 73 (2019) 100764]." Progress in retinal and eye research vol. (2020): 100857. doi: https://doi.org/10.1016/j.preteyeres.2020.100857
Munier FL, Beck-Popovic M, Chantada GL, Cobrinik D, Kivelä TT, Lohmann D, Maeder P, Moll AC, Carcaboso AM, Moulin A, Schaiquevich P, Bergin C, Dyson PJ, Houghton S, Puccinelli F, Vial Y, Gaillard MC, Stathopoulos C. Corrigendum to "Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "Alive, with good vision and no comorbidity"" [Prog. Retina Eye Res. 73 (2019) 100764]. Prog Retin Eye Res. 2020 Apr 08;100857. doi: 10.1016/j.preteyeres.2020.100857. Epub 2020 Apr 08. PMID: 32278633.
Copy Download .nbib Format: NLM
Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG).

Cancers

Stathopoulos C, Lumbroso-Le Rouic L, Moll AC, Parulekar M, Maeder P, Doz F, Jenkinson H, Beck Popovic M, Chantada G, Munier FL.
PMID: 34298608
Cancers (Basel). 2021 Jul 06;13(14). doi: 10.3390/cancers13143392.

Secondary enucleation (SE) puts an irreversible end to eye-preserving therapies, whenever their prolongation is expected to violate the presumed state of metastatic grace. At present, it must be acknowledged that clear criteria for SE are missing, leading to empiric...

Cite
Stathopoulos C, Lumbroso-Le Rouic L, Moll AC, et al. Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG). Cancers (Basel). 2021;13(14)doi: 10.3390/cancers13143392.
Stathopoulos, C., Lumbroso-Le Rouic, L., Moll, A. C., Parulekar, M., Maeder, P., Doz, F., Jenkinson, H., Beck Popovic, M., Chantada, G., & Munier, F. L. (2021). Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG). Cancers, 13(14), . https://doi.org/10.3390/cancers13143392
Stathopoulos, Christina, et al. "Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG)." Cancers vol. 13,14 (2021). doi: https://doi.org/10.3390/cancers13143392
Stathopoulos C, Lumbroso-Le Rouic L, Moll AC, Parulekar M, Maeder P, Doz F, Jenkinson H, Beck Popovic M, Chantada G, Munier FL. Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG). Cancers (Basel). 2021 Jul 06;13(14). doi: 10.3390/cancers13143392. PMID: 34298608; PMCID: PMC8303810.
Copy Download .nbib Format: NLM
Immune deficiency, autoimmune disease and intellectual disability: A pleiotropic disorder caused by biallelic variants in the TPP2 gene.

Clinical genetics

Atallah I, Quinodoz M, Campos-Xavier B, Peter VG, Fouriki A, Bonvin C, Bottani A, Kumps C, Angelini F, Bellutti Enders F, Christen-Zaech S, Rizzi M, Renella R, Beck-Popovic M, Poloni C, Frossard V, Blouin JL, Rivolta C, Riccio O, Candotti F, Hofer M, Unger S, Superti-Furga A.
PMID: 33586135
Clin Genet. 2021 Jun;99(6):780-788. doi: 10.1111/cge.13942. Epub 2021 Feb 21.

Four individuals from two families presented with a multisystemic condition of suspected genetic origin that was diagnosed only after genome analysis. The main phenotypic features were immune system dysregulation (severe immunodeficiency with autoimmunity) and intellectual disability. The four individuals...

Cite
Atallah I, Quinodoz M, Campos-Xavier B, et al. Immune deficiency, autoimmune disease and intellectual disability: A pleiotropic disorder caused by biallelic variants in the TPP2 gene. Clin Genet. 2021;99(6):780-788doi: 10.1111/cge.13942.
Atallah, I., Quinodoz, M., Campos-Xavier, B., Peter, V. G., Fouriki, A., Bonvin, C., Bottani, A., Kumps, C., Angelini, F., Bellutti Enders, F., Christen-Zaech, S., Rizzi, M., Renella, R., Beck-Popovic, M., Poloni, C., Frossard, V., Blouin, J. L., Rivolta, C., Riccio, O., Candotti, F., Hofer, M., Unger, S., & Superti-Furga, A. (2021). Immune deficiency, autoimmune disease and intellectual disability: A pleiotropic disorder caused by biallelic variants in the TPP2 gene. Clinical genetics, 99(6), 780-788. https://doi.org/10.1111/cge.13942
Atallah, Isis, et al. "Immune deficiency, autoimmune disease and intellectual disability: A pleiotropic disorder caused by biallelic variants in the TPP2 gene." Clinical genetics vol. 99,6 (2021): 780-788. doi: https://doi.org/10.1111/cge.13942
Atallah I, Quinodoz M, Campos-Xavier B, Peter VG, Fouriki A, Bonvin C, Bottani A, Kumps C, Angelini F, Bellutti Enders F, Christen-Zaech S, Rizzi M, Renella R, Beck-Popovic M, Poloni C, Frossard V, Blouin JL, Rivolta C, Riccio O, Candotti F, Hofer M, Unger S, Superti-Furga A. Immune deficiency, autoimmune disease and intellectual disability: A pleiotropic disorder caused by biallelic variants in the TPP2 gene. Clin Genet. 2021 Jun;99(6):780-788. doi: 10.1111/cge.13942. Epub 2021 Feb 21. PMID: 33586135.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries